On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
On February 14, 2013, the US Patent and Trademark Office (USPTO) released the relevant rules and associated guidelines pertaining to the ‘first inventor to file’ provisions of the America Invents Act (AIA). Th is article considers two sections of the new laws and associated rules and guidelines, which may particularly affect the life sciences industry and should be considered when conducting business.
Because of their reliance on investment funds, biotech companies often make public disclosures/press announcements regarding technology developments. In addition, the sale of technology is oft en important to life science companies. Th e following two sections of AIA 35 USC§102 will have important implications for the disclosure and/or sale of technology.
Sale of invention to create prior art
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
AIA, FITF, prior art, USPTO
